Literature DB >> 2454902

Papillary and follicular thyroid cancer: impact of treatment in 1578 patients.

W J Simpson1, T Panzarella, J S Carruthers, M K Gospodarowicz, S B Sutcliffe.   

Abstract

We report the experience from 13 Canadian radiotherapy centres concerning the treatment and outcome for 1074 papillary and 504 follicular thyroid cancer patients followed for 4-24 years. Surgical resection was carried out in almost all patients; there was no correlation between the type of operation and recurrence or survival. Treatment with external irradiation (201 patients) radioiodine (214 patients), or both (107 patients) was used more often in poor prognosis patients than in those with good prognostic factors, and was effective in reducing local recurrences and improving survival, especially in patients with microscopic residual disease postoperatively. Treatment complications were common but rarely fatal. Thyroid cancer was the cause of death in over half of the papillary cancer deaths and in two-thirds of the follicular cancer deaths.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454902     DOI: 10.1016/0360-3016(88)90381-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

Review 1.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

Review 2.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

Review 3.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

Review 4.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

5.  Comparison of prognostic scoring systems in follicular thyroid cancer.

Authors:  K W Teo; N K Yuan; W B Tan; R Parameswaran
Journal:  Ann R Coll Surg Engl       Date:  2017-07       Impact factor: 1.891

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

Review 7.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

Review 8.  The clinician and the thyroid.

Authors:  H J Biersack; A Hotze
Journal:  Eur J Nucl Med       Date:  1991

9.  Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.

Authors:  Jacqueline Jonklaas; Hala Nsouli-Maktabi; Steven J Soldin
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

10.  Metastatic thyroid carcinoma of the adrenal gland.

Authors:  M E Girelli; D Casara; D Rubello; M Piccolo; A Piotto; M R Pelizzo; B Busnardo
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.